Startups
Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.
Overview
Total raised
$82.6M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 5, 2026 | Cytospire Therapeutics Raises £61M in Series A Funding | Cytospire Therapeutics, a London, UK-based biotech company developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s own immune system, raised £61M in Series A funding. ... |
| Cytospire Therapeutics | “Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.” |
Reviews 0
FAQ about Cytospire Therapeutics Limited.
How much funding has Cytospire Therapeutics Limited. raised?
Cytospire Therapeutics Limited. has raised $82.6M in total across 1 funding round.
What has the press written about Cytospire Therapeutics Limited.?
Parsers VC has collected 3 articles mentioning Cytospire Therapeutics Limited., among them “Cytospire Therapeutics Raises £61M in Series A Funding” (May 5, 2026) and “Cytospire Therapeutics”.
Is Cytospire Therapeutics Limited. still active?
Yes, Cytospire Therapeutics Limited. is active; its latest activity on Parsers VC dates from Aug 2, 2026.